Table 3 Cox proportional hazards regression of all patients for progression-free survival and overall survival
Variables | Progression-free survival | Overall survival | ||
|---|---|---|---|---|
Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | |
Age > 65 | 1.11 (0.763 to 1.604) | 0.594 | 1.11 (0.653 to 1.894) | 0.694 |
Sex (male) | 0.94 (0.628 to 1.422) | 0.786 | 1.38 (0.787 to 2.407) | 0.263 |
Smoking | 1.08 (0.605 to 1.936) | 0.791 | 1.68 (0.820 to 3.450) | 0.156 |
EGFR mutation | ||||
 L858R | Reference |  | Reference |  |
 Del 19 | 0.97 (0.664 to 1.413) | 0.867 | 0.99 (0.558 to 1.772) | 0.985 |
 Uncommon mutation | 2.40 (0.851 to 6.753) | 0.098 | 3.75 (1.401 to 10.027) | 0.009 |
 Complex mutations | 3.12 (1.111 to 8.777) | 0.038 | 2.20 (0.645 to 7.523) | 0.208 |
Initial brain metastases number ≥ 3 | 1.17 (0.796 to 1.726) | 0.422 | 2.43 (1.277 to 4.629) | 0.007 |
Other metastases location | ||||
 Lung | 1.33 (0.921 to 1.918) | 0.129 | 1.56 (0.925 to 2.642) | 0.095 |
 Bone | 1.42 (0.963 to 2.090) | 0.077 | 1.70 (0.948 to 3.045) | 0.075 |
 Liver | 1.58 (0.981 to 2.558) | 0.060 | 2.03 (1.071 to 3.831) | 0.041 |
 Pleura | 1.33 (0.880 to 2.019) | 0.175 | 1.42 (0.808 to 2.495) | 0.223 |
 Other location | 1.84 (1.112 to 3.038) | 0.018 | 1.59 (0.818 to 3.085) | 0.172 |
M1c (definition by AJCC 8th edition) | 1.63 (0.812 to 3.269) | 0.169 | 1.55 (0.555 to 4.348) | 0.402 |
Radiotherapy to brain metastases | 0.78 (0.523 to 1.175) | 0.239 | 1.19 (0.690 to 2.064) | 0.527 |
Brain tumor excision | 0.75 (0.344 to 1.630) | 0.466 | 0.40 (0.097 to 1.645) | 0.204 |
PD location | ||||
 Intracranial only | Reference |  | Reference |  |
 Extracranial only | 1.10 (0.724 to 1.683) | 0.646 | 1.71 (0.903 to 3.259) | 0.100 |
 Both | 1.03 (0.537 to 1.978) | 0.927 | 0.90 (0.322 to 2.541) | 0.849 |
TKI | ||||
 Gefitinib | Reference |  | Reference |  |
 Erlotinib | 0.88 (0.584 to 1.324) | 0.539 | 1.14 (0.627 to 2.065) | 0.670 |
 Afatinib | 1.03 (0.620 to 1715) | 0.907 | 1.39 (0.642 to 3.001) | 0.404 |